Abstract:Type 2 diabetes (T2D) mellitus has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. Although medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these medicines are outdated, have severe side effects, and often become less efficacious over time, necessitating the need for insulin therapy. G protein–coupled receptors (GPCRs) regulate many physiologic processes, including blood glucose levels. In pancreatic β cells, GPCRs regulate β -cell growth, apoptosis, and insulin secretion, which are all critical in maintaining sufficient β -cell mass and insulin output to ensure euglycemia. In recent years, new insights into the signaling of incretin receptors and other GPCRs have underscored the potential of these receptors as desirable targets in the treatment of diabetes. The signaling of these receptors is modulated by GPCR kinases (GRKs) that phosphorylate agonist-activated GPCRs, marking the receptor for arrestin binding and internalization. Interestingly, genome-wide association studies using diabetic patient cohorts link the GRKs and arrestins with T2D. Moreover, recent reports show that GRKs and arrestins expressed in the β cell serve a critical role in the regulation of β -cell function, including β -cell growth and insulin secretion in both GPCR-dependent and -independent pathways. In this review, we describe recent insights into GPCR signaling and the importance of GRK function in modulating β -cell physiology. Significance Statement Pancreatic β cells contain a diverse array of G protein–coupled receptors (GPCRs) that have been shown to improve β -cell function and survival, yet only a handful have been successfully targeted in the treatment of diabetes. This review discusses recent advances in our understanding of β -cell GPCR pharmacology and regulation by GPCR kinases while also highlighting the necessity of investigating islet-enriched GPCRs that have largely been unexplored to unveil novel treatment strategies.

Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes

G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

G protein-coupled receptors as new therapeutic targets for type 2 diabetes

The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

Targeting the incretin system in obesity and type 2 diabetes mellitus

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes

Fatty acid receptors as new therapeutic targets for diabetes

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis

The role of gp130 receptor cytokines in the regulation of metabolic homeostasis

Does GIPR blockade as well as agonism have a role to play in management of obesity and diabetes?

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms